(Q84565156)

English

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone

scientific article published on 11 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Celestia Higano

4

object named as

Celestia Higano

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Joel B Nelson

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Karim Fizazi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kurt Miller

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Judd W Moul

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Hideyuki Akaza

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Thomas Morris

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Stuart McIntosh

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Kristine Pemberton

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Martin Gleave

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

11 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

5709-5718

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms leading to the development of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

The endothelin axis: emerging role in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Endothelin-1 inhibits apoptosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging treatment options for patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27674

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27674

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22786751%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84565156&oldid=2186392913"